Severe Chronic Cardiovascular Disease Focus

 Aastrom Biosciences
Description: Cardiovascular Disease, Autologus Stem cell Therapy, Late Phase 2 CLI Clinical development Program, cGMP quality Cell production system, Patient Safety Research Overview, Advantages of Aastrom Autologous Stem Cell Therapy, Targeting Niche Cardiovascular Disease Indications, High Unmet Medical Need, Restore CLI clinical Trial, CLI Interim Analysis, Dilated Cardiomyopathy DCM, Tissue Repair Cells Production and delivery, Future of Cardiovascular Disease Therapy
Views: 1737
Domain: Business
Category: Companies
Aastrom Biosciences
Focused on Severe Chronic Cardiovascular Diseases


Safe Harbor
This presentation contains forward-looking statements, including, without
limitation, statements concerning product-development objectives, clinical
trial strategies, clinical trial timing and expected results, market data,
potential market opportunities, market development plans, anticipated
milestones and pote ... See more

Recent Presentations

Dan Sapp Inc.
14 September, 2019
13 September, 2019
12 September, 2019